A COX-1 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mofezolac

Item No. 34102

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid
CAS Number
78967-07-4
Synonyms
  • N-22
Molecular Formula
C19H17NO5
Formula Weight
339.3
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: soluble
λmax
232 nm
SMILES
COC1=CC=C(C=C1)C2=C(CC(O)=O)ON=C2C3=CC=C(OC)C=C3
InChi Code
InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)
InChi Key
DJEIHHYCDCTAAH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $49

    Add

    10 mg

    $87

    Add

    25 mg

    $194

    Add

    50 mg

    $339

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Mofezolac is an inhibitor of COX-1 (IC50 = 14 nM).1 It is selective for COX-1 over COX-2 (IC50 = 440 nM). Mofezolac (1 µg/ml) protects against LPS-induced cell death in BV-2 microglia. In vivo, mofezolac (6 mg/kg, i.p.) reduces hippocampal microglial activation and prostaglandin E2 (PGE2; Item No. 14010) production in a mouse model of LPS-induced neuroinflammation. It reduces phenylquinone-induced writhing in a mouse model of acute pain.2 Dietary administration of mofezolac (1,200 ppm) reduces the number of aberrant crypt foci and tumors in a rat model of beef tallow diet-induced colon carcinogenesis.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Calvello, R., Lofrumento, D.D., Perrone, M.G., et al. Highly selective cyclooxygenase-1 inhibitors P6 and mofezolac counteract inflammatory state both in vitro and in vivo models of neuroinflammation. Front. Neurol. 8, 251 (2017).

    2. Goto, K., Ochi, H., Yasunaga, Y., et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 56(4), 245-254 (1998).

    3. Miao, L., Shiraishi, R., Fujise, T., et al. Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Hepatogastroenterology 58(105), 81-88 (2011).